pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

Changing Faces: Digital and supplier, February 2026

This month's round-up spans clinical trial technology, drug discovery AI, genomics, bioelectrical medicine, CDMOs, and non-profits.

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

R&D

GLP-1s: Five years that changed metabolic medicine

News

AZ piles pressure on MSD et al in gastric cancer

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.

News

Magnifying glass held by a human hand over a group of paper people cutouts in different colours

Denying prostate cancer screening 'no longer rational'

A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.

Featured Content

Digital

Changing Faces: Digital and supplier, February 2026

This month's round-up spans clinical trial technology, drug discovery AI, genomics, bioelectrical medicine, CDMOs, and non-profits.

R&D

GLP-1s: Five years that changed metabolic medicine

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Newsletters and Deep Dive
digital magazine

Latest News

News

AZ piles pressure on MSD et al in gastric cancer

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.

News

Denying prostate cancer screening 'no longer rational'

A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.

News

Data builds behind Bayer's Kerendia in kidney disease

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

Views & Analysis

Digital

Changing Faces: Digital and supplier, February 2026

This month's round-up spans clinical trial technology, drug discovery AI, genomics, bioelectrical medicine, CDMOs, and non-profits.

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

Sales & Marketing

Graphic illustration of hand holding launching rocket with dollar signs and a globe in the background

Execution drift: Why pharmaceutical go-to-market falls short...

Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another.

R&D

Changing Faces: Pharma and biotech, February 2026

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

GLP-1s: Five years that changed metabolic medicine

R&D

Redesigning obesity trials for a chronic disease era

R&D

The trust gap: GLP-1s and the new information economy of obe...

White Papers & Webinar

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Sales & Marketing

Lumanity white paper - person at top of mountain range

Sponsored

The strategic imperative of Integrated Evidence Generation P...

Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.

Digital

White paper from Veeva on Clinical Data Industry Research

Sponsored

Data managers and CRAs warn of rising data quality risks due...

A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.

Podcasts & Video

R&D

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Market Access